William Blair Has Negative Estimate for Amedisys Q1 Earnings

Amedisys, Inc. (NASDAQ:AMED) – Investment analysts at William Blair lowered their Q1 2025 earnings per share (EPS) estimates for Amedisys in a note issued to investors on Thursday, February 27th. William Blair analyst M. Larew now expects that the health services provider will post earnings per share of $0.98 for the quarter, down from their prior estimate of $1.01. The consensus estimate for Amedisys’ current full-year earnings is $4.40 per share. William Blair also issued estimates for Amedisys’ Q2 2025 earnings at $1.33 EPS, Q3 2025 earnings at $1.05 EPS, Q4 2025 earnings at $1.08 EPS and FY2025 earnings at $4.45 EPS.

Separately, Stephens reaffirmed an “equal weight” rating and issued a $101.00 price objective on shares of Amedisys in a research note on Wednesday, February 12th. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $100.75.

Amedisys Price Performance

Amedisys stock opened at $91.57 on Friday. The stock’s 50 day moving average is $91.26 and its 200 day moving average is $93.25. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19. The firm has a market cap of $3.00 billion, a P/E ratio of 36.34, a P/E/G ratio of 1.78 and a beta of 0.73. Amedisys has a one year low of $82.15 and a one year high of $98.95.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings data on Wednesday, February 26th. The health services provider reported $0.96 EPS for the quarter, missing analysts’ consensus estimates of $1.05 by ($0.09). The company had revenue of $598.05 million during the quarter, compared to analyst estimates of $602.38 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%.

Hedge Funds Weigh In On Amedisys

Institutional investors have recently added to or reduced their stakes in the business. Creative Planning grew its holdings in Amedisys by 12.6% during the third quarter. Creative Planning now owns 4,838 shares of the health services provider’s stock worth $467,000 after buying an additional 543 shares in the last quarter. State of Alaska Department of Revenue grew its holdings in Amedisys by 7.2% during the third quarter. State of Alaska Department of Revenue now owns 3,782 shares of the health services provider’s stock worth $365,000 after buying an additional 255 shares in the last quarter. Crossmark Global Holdings Inc. bought a new position in Amedisys in the 3rd quarter valued at $243,000. State of New Jersey Common Pension Fund D grew its stake in Amedisys by 1.7% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 20,357 shares of the health services provider’s stock valued at $1,965,000 after purchasing an additional 339 shares during the period. Finally, KBC Group NV bought a new position in Amedisys in the 3rd quarter valued at $63,000. 94.36% of the stock is owned by institutional investors and hedge funds.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.